Peer-reviewed articleOpen access

Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial

Reif A, Anıl Yağcıoğlu A, Luts A, Messer T, Nielsen R, Buyze J, Ito T, Kambarov Y, Mulhern Haughey S, Rive B, Usankova I, von Holt C, Godinov Y

European psychiatry : the journal of the Association of European PsychiatristsJul 19, 2023License: open access0 citations

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineDepression

View paper Full text (PDF)

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticleKetamine

Pharmacologic Approaches to Suicide Prevention.

Zisook S, Domingues I, Compton J

Europe PMC2023

ArticleKetamine

Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.

Drozdz SJ, Goel A, McGarr MW +6

Europe PMC2022

ArticleKetamine

Effects of ketamine on individual symptoms and symptom networks of depression in a randomised controlled trial of ketamine for treatment-resistant depression.

Hossein S, Rengasamy M, Uzamere A +5

Europe PMC2025